Ekso Bionics Holding ( (EKSO) ) has released its Q2 earnings. Here is a breakdown of the information Ekso Bionics Holding presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ekso Bionics Holdings, Inc. is a leading developer of exoskeleton technology designed to enhance human strength, endurance, and mobility for both medical and industrial applications. The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market.
In its latest earnings report for the second quarter of 2025, Ekso Bionics highlighted several strategic developments, including its acceptance into the NVIDIA Connect program and the launch of a new AI voice agent for its EksoNR device. Despite these advancements, the company experienced a decline in revenue compared to the previous year, primarily due to delays in Enterprise Health sales.
The company reported a revenue of $2.1 million for the quarter, a significant decrease from $5.0 million in the same period of 2024. This decline was attributed to lower sales of Enterprise Health devices, although there was a notable increase in sales of the Ekso Indego Personal device. The gross profit also fell to $0.8 million, with a gross margin of 40%, down from 53% the previous year. Operating expenses saw a slight decrease in sales and marketing costs, while general and administrative expenses increased.
Despite the financial challenges, Ekso Bionics is optimistic about the future, with plans to recover sales in the second half of the year and continue expanding its Personal Health products. The company remains committed to leveraging its strategic initiatives and partnerships to drive growth and innovation in the exoskeleton market.